Expression of deletion mutants of the breast and ovarian cancer-specific tumor suppressor protein, BRCA1, in the mammary epithelial cell line MCF10A revealed a powerful growth suppressive effect by a mutant that has the amino-terminal 302 amino acids deleted (DN-BRCA1). The growth suppression is associated with an increase in apoptosis and amplification in centrosome number. The growth inhibitory effect of DN-BRCA1 was not observed in cervical epithelial HeLa cells, suggesting that the phenotypes of BRCA1 mutant proteins differ depending on the cell line being tested. An internal domain, including BRCA1 residues 303-1292, caused the suppression of MCF10A cell growth, and the amino terminus of BRCA1 autoinhibited the growth suppression. Single point mutations that disrupted the amino-terminal RING domain of BRCA1 caused significant suppression of growth in MCF10A cells. These results suggest that the proper function of the RING domain, likely to be ubiquitin ligase function, is important in regulating the growth of the mammary epithelial cell line and in autoregulating the powerful internal growth-inhibiting domain of the BRCA1 tumor suppressor.
Introduction
The breast cancer tumor suppressor 1 (BRCA1) gene has been identified to be important as a cause of heritable breast cancer (Miki et al., 1994) . The emerging puzzle of BRCA1 is that, while its function is important for all cell types, when its function is lost only breast and ovarian cancers result (reviewed in Starita and Parvin, 2003) . A mechanistic understanding of how BRCA1 functions as a tumor suppressor protein remains unclear.
The BRCA1 protein has been found to have a large number of functions including the regulation of transcription and polyadenylation (Anderson et al., 1998; Haile and Parvin, 1999; Schlegel et al., 2000; Kleiman and Manley, 2001; Andrews et al., 2002; Narita et al., 2003; reviewed in Starita and Parvin, 2003) , chromatin remodeling (Hu et al., 1999; Bochar et al., 2000) , DNA damage repair (Moynahan et al., 1999; Scully et al., 1999; Snouwaert et al., 1999) , cell cycle progression (Somasundaram et al., 1997; Xu et al., 1999; MacLachlan et al., 2000) , and centrosome duplication (Xu et al., 1999; Hsu et al., 2001; Schlegel et al., 2003) . BRCA1 has been shown to have activities that include DNA binding (Paull et al., 2001 ) and ubiquitin ligase activity (Hashizume et al., 2001) . Since the ubiquitin ligase is an enzymatic activity, there is great interest in identifying the target(s) of this activity and the effects of the ubiquitin ligase on cell growth. Currently, it has been shown that BRCA1 together with BARD1 (BRCA1-associated RING domain protein) can monoubiquitinate histones and p53 (Chen et al., 2002; Dong et al., 2003) , but the significance of those ubiquitination activities is unknown.
BRCA1 has been shown to assemble into a number of protein complexes. It forms a heterodimer with BARD1 (Wu et al., 1996) . BRCA1 is associated with an RNA polymerase II complex (Scully et al., 1997; Neish et al., 1998) , suggestive of transcription function. BRCA1 associates with the RAD50/MRE11/NBS1 DNA repair complex (Zhong et al., 1999; Chiba and Parvin, 2001) and with the SWI/SNF chromatin remodeling complex (Neish et al., 1998; Bochar et al., 2000) . After arrest of replication using hydroxyurea, a new complex termed HUIC containing BRCA1 appears, and it is known to contain also BARD1 (Chiba and Parvin, 2001) . A complex named BRCC has recently been described that appears to link the DNA damage response with ubiquitination activity (Dong et al., 2003) .
In this study, we tested several deletion mutants of BRCA1, which we had previously developed (Chiba and Parvin, 2002) , for effects on cell growth when these proteins are modestly overexpressed. To our surprise, we found that one of the deletion mutants potently repressed cell growth, a surprising phenotype for a mutant of a tumor suppressor. We analysed the growth suppression phenotype of this mutant BRCA1 and reveal that an internal domain suppresses the growth of the breast tissue cell line, and the presence of the aminoterminal domain of BRCA1 counters the growth suppression caused by the internal domain. The growth suppression phenotype is associated with an increase in apoptosis and with amplification of centrosome number. Of interest, single point mutations of critical residues of the RING domain, which mediates ubiquitin ligase activity, partially mimicked the effects of the larger deletion mutant, suggesting that the ubiquitin ligase activity of BRCA1 is important in this phenotype. These results suggest that multiple contacts by BRCA1 are essential for its tumor suppressive effects. Much of the functional interest in BRCA1 has focused on the conserved amino-and carboxy termini, but the results in this study reveal that an internal domain of BRCA1 mediates a potent growth suppressive effect in a tissue culture cell line.
Results

Expression of an amino-terminal deletion mutant of BRCA1 inhibits the growth of MCF10A cells
We tested whether expression of BRCA1 deletion mutants in a cell line derived from normal, human mammary epithelia, MCF10A, caused abnormalities in the phenotype of these cells. Since MCF10A cells have normal BRCA1 function, we tested for dominant effects due to overexpression of BRCA1. The different BRCA1 deletion constructs ( Figure 1a ) were expressed using recombinant adenoviruses. These mutant proteins, when expressed similarly in HEK293 cells, had been shown to associate with the same protein complexes as does the endogenous BRCA1 protein, although the aminoterminal deletion mutant had significantly decreased binding to the RNA polymerase II complex (Chiba and Parvin, 2002) . Use of recombinant adenovirus has the advantage that every cell in the culture will overexpress BRCA1, and the levels of expression could all be normalized by adjusting the dose of virus used to induce protein expression. In order to determine the level of overexpression, the expressed BRCA1 was compared to the endogenous levels ( Figure 1b) . MCF10A cells were infected with BRCA1-expressing adenoviruses, and 24 h post infection (hpi) lysates were analysed by immunoblotting for BRCA1. For this experiment, the BRCA1-specific antibody used to detect the expressed protein was specific to an internal domain, and it should equally well recognize wild type, DN, and DC variants of BRCA1. BRCA1 in uninfected (Figure 1b, lane 1) or control virus-infected (lane 5) cells was observed as two specific bands migrating at a position consistent with a molecular mass of 220 and 200 kDa. Expression of the wild-type BRCA1 resulted in an increase in the intensity of the 220 kDa band (lane 2), and the DN and DC variants were observed as bands around 200 kDa (lanes 3 and 4). Based on the intensity of the bands, and based on comparison to the controls, the level of overexpression of BRCA1 used in these experiments was about fivefold over the endogenous protein. This level of expression should minimize the effects of nonspecific toxicity due to excessive accumulation of proteins. In subsequent experiments, the HA tag was used to compare the levels of the different deletion variants of BRCA1.
The panel of adenoviruses expressing deletion variants of BRCA1 was infected into MCF10A cells, and 24 hpi lysates were prepared to compare protein expression levels, and the cells were counted in parallel cultures for 3 days. Using cultures with balanced levels of protein Growth suppression by a dominant-negative BRCA1 mutant F You et al expression ( Figure 1c ), growth curves were determined ( Figure 1d ). As might be anticipated for a tumor suppressor protein, the expression of wild-type BRCA1 modestly suppressed the growth of the MCF10A cells. The deletion variants, D1, D2, and DC, caused similar growth curves as the wild-type BRCA1. By contrast, the DN-BRCA1-expressing cells did not grow. On multiple repeat experiments, the specific growth curves varied, but the trends were consistent. In every case, the DN-BRCA1-expressing cells grew at a significantly slower rate than the others, suggesting that deletion of aminoacid residues 1-302 of BRCA1 results in a gain of function inhibiting cell growth in MCF10A cells. This was a surprising result and suggested that one of the functions of this domain would be the autoinhibition of the potent growth suppression activity of another domain. Alternatively, since the ubiquitin ligase enzymatic activity of BRCA1 resides in its amino terminus, it was possible that DN-BRCA1 is a dominant-negative protein with a mutated enzymatic function. If that were true, however, it is surprising that a dominant-negative BRCA1 mutant tumor suppressor protein would result in cell death, rather than in unrestrained growth. This is especially true since ubiquitin-ligase-inactivating point mutations, such as C61G and C64G, are associated with breast cancer (Castilla et al., 1994; Friedman et al., 1994) . One cause of the loss of growth caused by overexpressing DN-BRCA1 in MCF10A cells could be apoptosis. Indeed, using an assay for DNA fragmentation as a marker for apoptosis, it was observed that the DN-BRCA1 expression resulted in a marked increase in apoptosis, whereas expression of other BRCA1 variants did not (Figure 2) .
Overexpression of the amino-terminal deletion mutant of BRCA1 caused centrosome amplification
We have found that BRCA1 regulates centrosome duplication in breast cell lines, such as MCF10A, but BRCA1 function is not required for normal centrosome regulation in non-breast cell lines (Schlegel et al., 2003;  Growth suppression by a dominant-negative BRCA1 mutant F You et al Starita et al., submitted) . We tested whether expression of DN-BRCA1 in MCF10A cells caused extra centrosomes. We found that, indeed, overexpression of DN-BRCA1 caused highly abnormal cells with lobulated nuclei and four centrosomes. MCF10A cells were infected with the appropriate recombinant adenovirus, and 3 days post infection, cells were fixed and stained using a primary antibody specific for g-tubulin (Figure 3 ) and for DNA (DAPI, data not shown). Examples of centrosome staining of cells expressing BRCA1 deletion variants are shown in Figure 3 . In panels a, c, d, e and f, several cells are shown in each field with either one or two centrosomes. By contrast, in the photomicrograph of cells expressing DN-BRCA1 (Figure 3b ), two cells are apparent with four centrosomes each. Quantitation of the many cells in the monolayer revealed that MCF10A cells had a background level of 2-5% of cells with abnormal centrosome numbers (greater than two), but when expressing the BRCA1 deletion variants, only DN-BRCA1 caused a significant increase in the number of cells with extra centrosomes (23%; Figure 3g ). These results were consistent with other findings that inhibition of BRCA1 using an inhibitory binding protein or by siRNA caused centrosome number amplification (Starita et al., submitted) . Earlier findings showed that a BRCA1 deletion strain of mice had centrosome abnormalities in the mutant fibroblasts (Xu et al., 1999) , and a g-tubulin-binding domain at residues 504-803 of BRCA1, when stably expressed in the COS cell line, caused centrosome overduplication (Hsu et al., 2001 ). The new results described here reveal that the modest overexpression of DN-BRCA1 causes centrosome amplification in a transient assay.
Expression of the BRCA1 amino-terminal mutant protein does not cause a cell growth defect in HeLa cells
We next asked whether another cell line would be similarly affected by the overexpression of BRCA1 deletion mutants. Toward this end, we repeated the experiments in Figure 1 , except in HeLa cells. It was found that expression of each of the BRCA1 variants similarly affected HeLa cell growth, and the effects on cell growth were indistinguishable from the effects of the LacZ-expressing control virus (Figure 4) . In this figure, the results from a single experiment are shown in two panels since the growth curves overlapped too much for clarity. The wild-type BRCA1-expressing cells and the DN-BRCA1-expressing cells clearly had minimal effects on the growth of HeLa cells ( Figure 4B(a) ). In these experiments, D1-BRCA1, D2-BRCA1, and the LacZ-expressing control all had modest effects on HeLa cell growth, which we interpret to be insignificant ( Figure 4B(b) ). Similar results were obtained with U2OS osteosarcoma cell line (data not shown). Thus, the growth suppression effects of the DN-BRCA1 expression were specific for the MCF10A breast cell line among the cell lines tested.
An internal domain of BRCA1 caused growth suppression in MCF10A cells
We next asked which domain of BRCA1 was responsible for the powerful growth suppression revealed by deletion of the amino terminus of BRCA1. Proteins that interact with BRCA1 bind to domains throughout the length of the protein, although many cluster in the carboxy terminus. Indeed, we have found that the RNA polymerase II holoenzyme complex binds to BRCA1 by both the amino-and carboxy termini of the BRCA1 protein (Chiba and Parvin, 2002) . In addition, inhibiting BRCA1 function by expression of a protein fragment that binds to the BRCA1 carboxy terminus caused a similar amplification of centrosome number (Schlegel et al., 2003; Starita et al., submitted) . We thus hypothesized that the growth suppression effects of the DN-BRCA1 mutant protein were dependent on a protein domain in the carboxy terminus. We generated recombinant adenoviruses, which separately deleted each domain in addition to DN-BRCA1 (Figure 5a ). When DN þ DC-BRCA1 was expressed in MCF10A cells, there was no change in growth suppression, when compared to the effects of DN-BRCA1 ( Figure 5 ). By comparison, deletion of either internal domain cancelled Growth suppression by a dominant-negative BRCA1 mutant F You et al the growth suppression caused by expression of the DN-BRCA1 domain. The simplest explanation for these results was that the D1 and D2 deletions include a single domain that is contained within amino-acid residues 303-1292. Taken together with the results of Figure 1 , this internal domain suppressed growth, and this growth suppression was in turn inhibited by the amino-terminal domain, containing the RING domain.
Mutation of the amino-terminal RING domain caused growth suppression in MCF10A cells
The DN-BRCA1 protein deleted amino-acid residues 1-302 of BRCA1. The deleted domain included the RING domain, which binds to the BARD1 protein and which has ubiquitin ligase activity (Hashizume et al., 2001; Wu-Baer et al., 2003; Xia et al., 2003) . We tested whether the ubiquitin ligase function was the critical activity deleted from DN-BRCA1 by generating specific point mutations of critical cysteines. We found that expression of BRCA1 mutated at cysteine-61 or at cysteine-64 resulted in a partial inhibition of cell growth when compared to the effects of DN-BRCA1 and the wild-type BRCA1 (Figure 6 ). This result suggested that the ubiquitin ligase activity of BRCA1 was important in the regulation of cell growth, and some other activity encoded in the amino terminus of BRCA1 was also important in this assay.
Discussion
In this study we found that overexpression of a BRCA1 mutant protein in a mammary cell line with normal endogenous BRCA1 protein caused a dominant growth inhibition. This growth phenotype was associated with loss of cell growth, apoptosis, and centrosome number amplification. The effects on cell growth of expression of this BRCA1 mutant protein were not observed in HeLa cells, suggesting that this finding is specific to a subset of cell lines. The deleted amino-terminal domain is known to be critical for the ubiquitin ligase activity of BRCA1. It was thus tested whether single amino-acid changes, which are known to abrogate the ubiquitin ligase activity of BRCA1, would similarly inhibit the growth in MCF10A cells, and it was found that the expression of these point mutant BRCA1 proteins caused significant growth suppression, but not to the same extent as the deletion mutant. It is thus likely that a second feature of the amino terminus, in addition to the ubiquitin ligase activity, is important in this phenotype. Taken together, these data demonstrate a dominantnegative effect of BRCA1 mutation, and it is shown that mutations that abrogate the ubiquitin ligase activity also mediate the dominant-negative phenotype. It is surprising that the dominant-negative BRCA1 results in growth suppression since it is a tumor suppressor. A counter-example for a tumor suppressor is p53. With this protein, dominant-negative mutations, which abrogate DNA-binding activity, also cause an increase Growth suppression by a dominant-negative BRCA1 mutant F You et al in growth (reviewed in Ko and Prives, 1996) , not the growth suppression seen in this study with BRCA1. We found that an internal domain within BRCA1 aminoacid residues 303-1292 mediates the powerful growth suppression in MCF10A cells. Since mutation at cysteine 61 or cysteine 64 is associated with breast cancer (Castilla et al., 1994; Friedman et al., 1994) , it is surprising that mutation of this domain caused growth suppression. We suggest that those cells that escape the growth suppressive effects of these mutations are transformed. Part of the internal domain has been shown to bind to g-tubulin, and the stable overexpression of this BRCA1 protein fragment in COS cells results in apoptosis and extra centrosomes (Hsu et al., 2001) . This phenotype is similar to that observed in this study, but in this study we demonstrate that the amino terminus of BRCA1, containing the RING domain, autoinhibits the effects of the internal domain. It is possible that the key growth suppression domain in this study depends on BRCA1 residues that encompass the g-tubulin-binding domain, containing residues 504-803 (Hsu et al., 2001) . This domain straddles the boundary of the two internal deletions that we tested. Experiments are in progress to test this hypothesis.
The amino terminus of BRCA1 contains the RING domain, an E3 ubiquitin ligase (Hashizume et al., 2001; Xia et al., 2003) , and a specific target for ubiquitination has recently been found to be the centrosome. BRCA1, together with BARD1, ubiquitinates the g-tubulin polypeptide itself (Starita et al., submitted) . In that study, it was found that inhibiting the centrosomespecific ubiquitination activity of BRCA1 resulted in extra centrosomes in breast-derived tissue culture cells, such as MCF10A. In the current study, the ubiquitination activity was lost by deletion in DN-BRCA1. Since DN-BRCA1 still contains the g-tubulin-binding domain, it could function in a dominant fashion to block the effects of BRCA1 ubiquitin-ligase-dependent inhibition of centrosome duplication.
The results of this study reveal the functional interplay of two domains of the BRCA1 protein that regulate the growth of a mammary cell line. Our data show that a major function of the amino terminus of BRCA1 is to autoinhibit the growth suppressive function of a second domain. One possible mechanism for the autoinhibition of the BRCA1 growth suppression is that the aminoterminal RING domain of BRCA1 modifies, via ubiquitination, the activity of the internal growth suppression domain. Current experiments are aimed at testing this hypothesis.
Materials and methods
Cell lines and adenoviruses
The normal mammary epithelial cell line, MCF10A (CRL-10317), and the cervical cancer cell line, HeLa (CCL-2), were obtained from the ATCC and grown using recommended media. Many of the recombinant adenoviruses expressing BRCA1 deletion mutants used in this study have been described previously (Chiba and Parvin, 2002) , and other deletion mutations of BRCA1 were made using the Ad-Easy (Q-Biogene) kit according to the manufacturer's instructions. Point mutations in BRCA1 were generated using the QuickChange kit (Stratagene). Adenovirus recombinants were amplified from isolated plaques in HEK293 cells, and the virus was titered by plaquing on HEK293 cells. In the case of the BRCA1-C61G-and BRCA1-C64G-expressing viruses, the titer was determined by measuring the tissue culture infectious dose, as per Q-Biogene protocols. The amount of BRCA1-expressing virus used to infect a culture was determined empirically to yield a modest overexpression relative to the endogenous protein. BRCA1 mutant-expressing viruses were balanced for protein expression levels. When expressing BRCA1 proteins in MCF10A cells, the multiplicity of infection (MOI) ranged from 50 to 200 virus particles per cell. The control virus, expressing LacZ, was infected at the highest MOI of 200. When expressing BRCA1 proteins in HeLa cells, the MOI ranged from 50 to 260 virus particles per cell.
Cell growth assay
MCF10A cells (5 Â 10 5 cells) or HeLa cells (2 Â 10 5 cells) were infected in triplicate with adenovirus on day 0. On each day, cells were suspended from the monolayer using trypsin and counted. On day 1, the cells were lysed in buffer containing sodium dodecylsulfate, protein concentrations were measured, and protein from 2 Â 10 5 cells was analyzed by SDS-PAGE and immunoblotting. Apoptosis was measured using the Cell Death Detection ELISA kit (Roche Diagnostics).
Fluorescence microscopy
Centrosome number was determined by fixing and staining cells according to published procedures (Schlegel et al., 2003) . Cells were stained with rabbit anti-gamma-tubulin antibody (Sigma) and detected using secondary antibody coupled to Texas red (Jackson Labs). Using a Nikon Eclipse TE2000-S microscope, at least 200 cells were counted for each BRCA1 mutant.
